Endovas Medical Completes New Round of Financing to Advance Innovative Solutions for Peripheral Venous Diseases
Shanghai Ensheng Medical Technology Co., Ltd. has successfully completed a significant round of financing at the beginning of the new year. This equity financing round, following the previous one that raised nearly RMB 100 million, marks an important milestone in the company’s development journey.
This investment involves the joint establishment of a specialized venture capital fund by Anhui Xinhua Group Investment Co., Ltd. and professional investors, with a financing scale reaching tens of millions of yuan. Upon completion of this financing round, Ensheng Medical will accelerate the promotion and development of its domestic sales network, advance new product registrations, and explore pathways for international market expansion, among other key initiatives.
The year 2024, which has just passed, was a year of significant importance in the development process of Ensheng Medical. In April, the company officially obtained certification and launched the V-Mixtent, featuring a uniquely innovative structure.®Venous Stent: This “meticulously crafted” venous stent pioneers an innovative manufacturing process combining laser engraving with braiding. In December 2024, during the fifth national centralized procurement for the “Peripheral Vascular Stents – Venous Stents” category, it stood out among more than ten renowned domestic and international manufacturers, winning the bid at the highest price within its group, thereby attracting significant attention and interest from the industry. Since its inception, Ensheng Medical has undergone six years of rigorous development and has now gained industry recognition in the niche field of peripheral venous therapy.
In the field of peripheral venous disease treatment, imported products have long held a dominant position. Taking venous stents as an example, products from foreign brands such as Boston Scientific and Bard occupy the majority of the market share in domestic clinical practice. However, with the development of medical innovation in China and the support of industrial capital, products from domestic enterprises are gradually emerging in this field, among which Ensheng Medical’s V-Mixtent®Venous stents are among the best in class.
V-Mixtent®Venous StentUtilizing advanced manufacturing processes and high-quality biocompatible materials, the product ensures superior performance and safety. Compared with other competing products on the market, this stent offers the following significant advantages:
1. Comprehensive Indications: V-Mixtent®The venous stent is an all-indication venous stent, indicated for the treatment of non-thrombotic iliac vein compression syndrome (NIVCS), deep vein thrombosis (DVT), and post-thrombotic syndrome (PTS).
2. The stent adopts an organic combination of laser-cut and braided designs: the laser-cut segment provides strong support, ensures outflow tract patency while anchoring the braided stent, and enables precise positioning during deployment through a hybrid structure of open-cell and closed-cell designs, thereby preventing forward jumping of the stent;
3. Ensheng Medical’s venous stents are available in a comprehensive range of sizes and specifications, including an ultra-long 150 mm stent capable of covering complex lesions.
In addition, Ensheng Medical's independently developedVenous Closure System and V-CLOFF®Deep Vein Thrombosis Removal SystemClinical enrollment has been fully completed. The company has established a dedicated team to oversee the regulatory approval and registration of these two products, aiming to secure marketing authorization and launch them as early as possible.
V-CLOFF®Deep Vein Thrombosis Removal SystemInterventional procedures performed via popliteal/femoral vein puncture for the removal of deep vein thrombosis. This product employs a novel stent-based thrombectomy approach, utilizing a self-expanding nitinol thrombectomy stent derived from the company’s commercially available V-Mixtent product.®The venous stent features a pioneering modular platform technology that combines laser-engraved and braided structures. The laser-engraved segment conforms closely to the vessel wall, facilitating efficient thrombus separation, while the dense braided segment is designed for effective thrombus capture. When used in conjunction with negative-pressure aspiration, this system enables rapid ex vivo removal of thrombi, proving particularly effective for challenging subacute thrombi that are firmly adherent to the vessel wall. Compared to existing aspiration thrombectomy devices, this approach offers a more efficient and safer procedural experience, with reduced blood loss and decreased reliance on thrombolytic agents, thereby lowering the risk of complications. It provides an improved therapeutic option for patients with acute and subacute deep vein thrombosis (DVT).
Ensheng Medical's pioneering development in ChinaVaricose Vein Closure SystemUsed for the treatment of lower extremity varicose veins, this non-thermal therapeutic approach offers enhanced safety and convenience compared to existing procedures. It features shorter operative times, eliminates the need for tumescent anesthesia during surgery, and results in fewer side effects. Patients can resume ambulation immediately after the procedure, thereby improving clinical workflow efficiency.
At this point, Ensheng Medical hasIliac Vein Compression Syndrome, Venous Thromboembolism, Varicose VeinsProduct layout has been achieved in the three major fields of minimally invasive interventional therapy, providing strong support for the company's fusion and development.
Mr. Wang Shengqiang, Founder of Ensheng Medical, expressed his sincere gratitude to investors for their recognition of Ensheng Medical. Both previous-round and current-round investors have provided financial support and facilitated resource connections to fuel the company’s growth. He believes that this financing round will accelerate the commercialization of the company’s R&D achievements, providing solid support for Ensheng Medical in areas such as R&D innovation, market expansion, and talent acquisition. Mr. Wang stated that this funding will significantly promote the promotion and development of the company’s domestic sales network, enabling its products to serve patients across China more quickly and effectively. Meanwhile, it will also accelerate the registration process for new products, further enhancing the company’s position within the industry. Most importantly, it provides a guarantee for exploring pathways into international markets, helping the company expand overseas and collaborate with global medical institutions to address the challenges of venous disease treatment, thereby benefiting more patients.
Representatives of Anhui Xinhua Investment, a lead investor in this round, also expressed active and steadfast support and strong confidence in Ensheng Medical. The investors highly recognize Ensheng Medical’s technical capabilities and commercial value. In their view, the company demonstrates outstanding R&D and innovation capabilities in the field of peripheral venous diseases, with its products holding broad market prospects. The investors are not only optimistic about the company’s short-term development but also firmly confident in its long-term potential, and they will actively assist Ensheng Medical in identifying industry opportunities and expanding its resource network.
Looking ahead, the Company will actively recruit top talent to build a professional and efficient sales and marketing team. By continuously increasing R&D investment, it will deepen technological innovation in the field of vascular medical devices, thereby enhancing product quality and performance. Meanwhile, the Company will further strengthen collaborations with domestic and international research institutions and key hospitals to promote deep integration of industry, academia, and research. In terms of market expansion, Ensheng Medical will actively explore both domestic and international markets to increase its market share. Through these efforts, Ensheng Medical is poised to become an emerging force in the treatment of peripheral venous diseases both at home and abroad, contributing to the advancement of healthcare.
Shanghai Ensheng Medical Technology Co., Ltd., established in 2018, is a high-tech enterprise dedicated to providing comprehensive solutions for the treatment of peripheral venous diseases. Integrating research and development with manufacturing, the company is an innovative high-tech medical enterprise holding over one hundred independent intellectual property rights. Leveraging its outstanding performance in the R&D and industrialization of vascular medical devices at internationally advanced levels, Ensheng Medical has built three core platforms—modular stent design, biomedical materials, and active medical devices—to comprehensively develop holistic solutions for peripheral venous diseases. The company is committed to delivering high-end medical devices that benefit the general public to clinicians and patients alike.
Anhui Xinhua Group Investment Co., Ltd. has made strategic investments in the healthcare and intelligent manufacturing sectors, with portfolio companies such as Qihao Medical and Jiaxuan Intelligence achieving outstanding performance within their respective niche markets. Anhui Xinhua Group Investment Co., Ltd. is a subsidiary of Anhui Xinhua Group, which was founded in 1988 and is headquartered in Hefei. Over the past three decades, the Group has consistently upheld its noble mission of “Xinhua Education, Serving the Country and Its People” and adhered to the Xinhua spirit of “Unity, Pragmatism, Innovation, and Dedication.” It has since evolved into an international, modern enterprise group centered on education, while integrating technology, finance, and investment. The Xinhua Group owns two listed companies: China Xinhua Education (02779.HK) and China East Education (00667.HK).